Michelle Carr, Author at BioTuesdays

Developments

Vaccine publishes study demonstrating benefits of PharmaJet’s Tropis needle-free system

Closely held PharmaJet announced the publication of a study in the top-tier journal Vaccine, which demonstrates the benefits of the company’s Tropis needle-free system compared to needle and syringe (N/S) for...

May 1, 2025

Developments

eGenesis and OrganOx report FDA clearance of IND application for ACLF treatment

Closely held eGenesis and OrganOx announced that the FDA has cleared the IND application for EGEN-5784—a human-compatible, genetically engineered porcine liver—designed for use in combination with the OrganOx...

April 15, 2025

Developments

Mayo study validates Aditxt’s ADI-100 induces immune tolerance to GAD

Aditxt (NASDAQ:ADTX) announced that a Mayo Clinic study has confirmed ADI-100 induces immune tolerance to glutamic acid decarboxylase (GAD)—a key autoantigen connected to multiple autoimmune conditions including Type 1...

April 14, 2025

Developments

Chamath Palihapitiya Discusses Perimeter Medical’s AI-Driven Cancer Margin Imaging on Flagrant Podcast

During a recent episode of the Flagrant podcast hosted by Andrew Schulz and Akash Singh, investor and entrepreneur Chamath Palihapitiya offered a compelling example of how medical innovation can drive meaningful...

April 10, 2025

Executive Moves

Brian Donnelly joins Myriad as CCO

Myriad Genetics (NASDAQ:MYGN) announced it has appointed Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. Mr. Donnelly brings more than 20 years of leadership experience in healthcare...

April 8, 2025

Developments

Atossa announces plan to pursue MBC indication for (Z)-endoxifen

Atossa Therapeutics (NASDAQ:ATOS) announced its decision to pursue a metastatic breast cancer (MBC) indication for (Z)-endoxifen. According to Attosa, it also plans to work with the FDA to advance additional...

March 11, 2025

Developments

Covenant Health Fort Sanders first in Tennessee to use Perimeter’s pioneering AI-driven OCT cancer margin visualization technology

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX:PYNKF) announced that Covenant Health Fort Sanders Regional is the first hospital in Tennessee to implement its optical coherence technology (OCT) technology, S-Series...

March 6, 2025

Developments

Personalis spotlights new publication from ICR and Royal Marsden on ctDNA testing in MRD

Personalis (NASDAQ:PSNL) in collaboration with the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Foundation Trust, UK, has announced published results from its early-stage breast cancer study in...

March 3, 2025

Executive Moves

Andrew Gengos joins Terns as CFO

Terns Pharmaceuticals (NASDAQ:TERN) has announced the appointment of Andrew Gengos as chief financial officer (CFO), effective immediately. Mr. Gengos brings 25 years of leadership experience in life sciences and...

February 25, 2025

Developments

FDA fast tracks BioRestorative’s BRTX-100 in cLDD

BioRestorative Therapies (NASDAQ:BRTX) has announced that the FDA has granted Fast Track designation to the BRTX-100 stem cell program for the treatment of chronic lumbar disc disease (cLDD). “We are thrilled that the...

February 20, 2025

Author - Michelle Carr

Vaccine publishes study demonstrating benefits of PharmaJet’s Tropis needle-free system

eGenesis and OrganOx report FDA clearance of IND application for ACLF treatment

Mayo study validates Aditxt’s ADI-100 induces immune tolerance to GAD

Chamath Palihapitiya Discusses Perimeter Medical’s AI-Driven Cancer Margin Imaging on Flagrant Podcast

Brian Donnelly joins Myriad as CCO

Atossa announces plan to pursue MBC indication for (Z)-endoxifen

Covenant Health Fort Sanders first in Tennessee to use Perimeter’s pioneering AI-driven OCT cancer margin visualization technology

Personalis spotlights new publication from ICR and Royal Marsden on ctDNA testing in MRD

Andrew Gengos joins Terns as CFO

FDA fast tracks BioRestorative’s BRTX-100 in cLDD

Subscribe